Cecilia Akatukwasa
ID: UNCST-2024-R002112
|
Feasibility and acceptability of the Vxnaid-Immunization Information System (Vxnaid-IIS) for improved Immunization Monitoring and Data Management through Digitization in Wakiso district.
REFNo: SS3734ES
4. To explore stakeholder’s insights and perspectives into future use of Vxnaid-Immunization Information System including sustainability,3. To assess the barriers and enablers to implementation of the Vxnaid-Immunization Information System across four HSDs and four Municipal councils in Wakiso district.,2. To explore key stakeholders’ perceptions, attitudes and acceptance of the Vxnaid-Immunization Information System,1. Explore key stakeholders’ perspectives on practicality, ease of use and overall experience with integrating Vxnaid into current Immunization Information systems across four HSDs and four Municipal councils in Wakiso district.,
|
Uganda |
2025-04-02 9:08:21 |
2028-04-02 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
William Blackmon
ID: UNCST-2025-R017006
|
Consumer Protection Surveys - Uganda
REFNo: SS3650ES
The project aims to:
• Measure consumer protection risks associated with digital financial services (DFS) usage in Uganda
• Track consumer protection risks across two survey rounds
• Create a comparable cross-country analysis (the survey is also carried out in 10 other countries)
|
USA |
2025-04-02 9:06:12 |
2028-04-02 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Maxensia owor
ID: UNCST-2021-R014003
|
An open-label randomised controlled trial comparing novel combination and currently used antibiotic regimens for the empiric treatment of neonatal sepsis with a run-in confirmatory pharmacokinetic phase: NeoSep1
REFNo: HS5639ES
In Part 2, a secondary objective is to provide a ranking of clinically relevant antibiotic regimens based on other efficacy and safety secondary outcomes, as well as on health economic measures and the potential selection of resistance. The trial data will provide data to inform the balance between efficacy, safety, costs (and cost-effectiveness and equity, using health economic analysis) and propensity for resistance selection (based on microbiology tests) that will influence facility-level and national decision-making about adoption of studied regimens, and potential future inclusion in WHO guidelines.,In Part 2, the primary objective is to provide a ranking of eight different clinically relevant antibiotic regimens for first-line empiric and second-line (after lack of response/deterioration) treatment in terms of 28-day mortality as the primary outcome measure. It will flexibly compare these multiple different relevant treatment regimens to enable the trial to be run in sites worldwide with very different background rates of different pathogens, of resistance and patterns of routine clinical care by randomising each participant to locally relevant antibiotic regimens agreed prior to site initiation. The trial will ensure generalisability by focusing inclusion based on clinical symptoms associated with high mortality risk in the NeoOBS study, which have been developed into a novel neonatal sepsis severity score – the NeoSep Severity Score.,
|
Uganda |
2025-04-02 9:04:16 |
2028-04-02 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Gloria Lubega
ID: UNCST-2025-R017180
|
A retrospective review of patients admitted with SARS-COV-2 at Entebbe regional referral hospital in Uganda across multiple waves.
REFNo: HS5695ES
I. To evaluate the mortality rate, risk factors associated with mortality and prolonged hospital admission among patients admitted with severe COVID-19 disease at ERRH.
II. To determine the time to discharge of patients admitted with severe COVID-19 disease at ERRH.
III. To describe the characteristics of patients across different age groups admitted with severe COVID-19 at Entebbe Regional Referral Hospital
IV. To describe treatment options offered to patients admitted with severe COVID-19 disease with reference to Uganda MoH and WHO recommended treatment options.
V. To compare characteristics of patients who were vaccinated against COVID-19 admitted with severe disease and unvaccinated patients admitted with severe COVID-19 disease.
|
Uganda |
2025-04-02 9:01:54 |
2028-04-02 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Mark Kaddumukasa
ID: UNCST-2020-R001798
|
Building a Collaborative Research and Training Platform for HIV and Rheumatic and Musculoskeletal Diseases in Uganda
REFNo: HS5606ES
Objective 1. Establish the Ugandan Registry of RMDs in HIV (GEMINI), to create a foundation for future prospective studies on HIV and RMDs.
Objective 2. In a pilot study, among a subset of participants from GEMINI with both RA and HIV, compared to participants with HIV only and RA only, explore the impact of co-morbid disease status on markers of bone metabolism, bone mineral density, as well as quality of life and functional disability.
|
Uganda |
2025-04-02 9:00:14 |
2028-04-02 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|